Tema Etfs LLC Invests $2.23 Million in DexCom, Inc. (NASDAQ:DXCM)

Tema Etfs LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, HoldingsChannel reports. The fund acquired 28,643 shares of the medical device company’s stock, valued at approximately $2,228,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in DexCom in the fourth quarter valued at approximately $385,367,000. Congress Asset Management Co. grew its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD bought a new position in shares of DexCom during the fourth quarter valued at approximately $96,507,000. Northern Trust Corp grew its holdings in shares of DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. This represents a 4.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company’s stock, valued at $26,183,401.02. This trade represents a 8.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock worth $4,734,384 over the last ninety days. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent research reports. Mizuho initiated coverage on DexCom in a report on Thursday, April 10th. They set an “outperform” rating and a $85.00 target price for the company. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Robert W. Baird lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $98.11.

DexCom Stock Performance

DXCM opened at $85.48 on Friday. The company has a market capitalization of $33.52 billion, a price-to-earnings ratio of 59.78, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.09. The business has a 50 day moving average price of $72.01 and a two-hundred day moving average price of $77.64.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.